SARS-CoV-2-IN-124

SARS-CoV-2-IN-124 (Compound 10) (0-20 μM) exhibits potent anti-SARS-CoV-2 activity against both the prototype strain and the BA.1 SARS-CoV-2 strain in Vero cells, with corresponding EC₅₀ values of 0.9 μM and 0.5 μM respectively, and shows low associated cytotoxicity (CC₅₀ = 44.1 μM)^[1].
SARS-CoV-2-IN-124 (8 μM) completely inhibits the expression of the SARS-CoV-2 nucleocapsid protein in infected Vero cells^[1].
SARS-CoV-2-IN-124 (8 μM; 24-48 h post-infection) significantly inhibits the viral RNA replication of SARS-CoV-2 in infected Huh-7 and Caco-2 cells at 24 h and 48 h post-infection^[1].
SARS-CoV-2-IN-124 (2-8 μM; 48 h) downregulates the expression of lipogenic enzymes FASN and SCD1 in Huh-7 and Caco-2 cells in a dose-dependent manner under multiple infection conditions^[1].
SARS-CoV-2-IN-124 (8 μM; 24 h) promotes the lysosome-dependent degradation of NCOA1 protein, while the proteasomal degradation pathway is not involved in this process^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.